As the pharmaceutical industry faces mounting scrutiny over drug pricing, GlaxoSmithKline Plc Chief Executive Officer Andrew Witty touted innovation as the best defense and pledged to highlight a product pipeline next month that would help withstand pressure from payers.
About 80 percent of the U.K. drugmaker’s pipeline is made up of first-in-class candidates, including an antibiotic in a new drug category to be discussed at a research and development presentation for investors on Nov. 4, Witty said at an event in London late Thursday.
Help employers find you! Check out all the jobs and post your resume.
